Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data
Chun‐Ting Yang, Wenyu Yao, Huang‐Tz Ou, Shihchen Kuo
Topics & Concepts
MedicineCohortType 2 diabetesCost-effectiveness analysisHealth careDiabetes mellitusQuality-adjusted life yearCost effectivenessInternal medicineIntensive care medicineEndocrinologyRisk analysis (engineering)Economic growthEconomicsDiabetes Treatment and ManagementMedication Adherence and ComplianceHyperglycemia and glycemic control in critically ill and hospitalized patients